8 active not recruiting. 8 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Active not recruiting 8 |
| Phase 1 | 3 | Active not recruiting 3 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Glaucoma: new trials by email Literature Review of Glaucoma trials Research Report on Glaucoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%) - Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG) | Phase 2 | Active not recruiting | Qlaris Bio, Inc. | 14 | 2026-02-20 | 2026-09-14 |
| Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension PA5108 Ocular Implant low dose, PA5108 Ocular Implant, high dose, Latanoprost 0.005% Ophthalmic Solution - Glaucoma, Open-Angle, Ocular Hypertension | Phase 2 | Active not recruiting | PolyActiva Pty Ltd | 75 | 2025-05-31 | 2026-07-08 |
| Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution Bimatoprost Implant System (High Dose), Bimatoprost Implant System (Low Dose), Timolol Maleate Ophthalmic Solution, 0.5% - Cataract, Glaucoma | Phase 1 / Phase 2 | Active not recruiting | SpyGlass Pharma, Inc. | 201 | 2023-10-13 | 2025-08-22 |
| Nicotinamide and Pyruvate for Open Angle Glaucoma: A Randomized Clinical Study Dietary supplements - Nicotinamide and Pyruvate, Placebo - Primary Open Angle Glaucoma | Phase 2 / Phase 3 | Active not recruiting | Columbia University | 250 | 2023-03-14 | 2026-07-15 |
| Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients. Kinezodianone R hydrochloride, Placebo - Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | Laboratoires Thea | 120 | 2022-07-05 | 2024-02-07 |
| Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for Glaucoma NT-501, Sham comparator - Glaucoma | Phase 2 | Active not recruiting | Stanford University | 30 | 2021-05-15 | 2025-11-04 |
| AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension AGN-193408 SR, Lumigan, Sham Administration - Open-angle Glaucoma, Ocular Hypertension | Phase 1 / Phase 2 | Active not recruiting | AbbVie | 100 | 2020-11-16 | 2026-05-22 |
| Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision Restoration NT-501 ECT implant, Sham - Glaucoma | Phase 2 | Active not recruiting | Stanford University | 54 | 2016-06-01 | 2025-11-04 |
Glaucoma, Open-Angle (4) · Ocular Hypertension (4) · Cataract (1) · Diabetic Retinopathy (1) · Low Tension Glaucoma (1)
Eye Diseases (8) · Ocular Hypertension (4) · Cardiovascular Diseases (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Angiopathies (1) · Endocrine System Diseases (1) · Lens Diseases (1) · Optic Nerve Diseases (1) · Retinal Diseases (1) · Vascular Diseases (1)
Bimatoprost (1) · Latanoprost (1) · Ophthalmic Solutions (1) · Pyruvic Acid (1) · salicylhydroxamic acid (1)
Stanford University (2) · AbbVie (1) · Columbia University (1) · Laboratoires Thea (1) · PolyActiva Pty Ltd (1) · Qlaris Bio, Inc. (1) · SpyGlass Pharma, Inc. (1)
United States (8) · Japan (1)
Aakriti G. Shukla, MD (1) · Barbara M Wirostko, MD (1) · Chris Hafner (1) · Jeffrey L Goldberg, MD, PhD (1)